CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ: CERS) announced today that the Belgian Red
Cross Flanders (RC-F) has signed a five-year agreement to purchase the
INTERCEPT Blood System for platelets. RC-F is one of two major Red Cross
blood services in Belgium, and supplies approximately 37,000 platelet
components to the northern, or Flemish, region of Belgium.
“We believe that INTERCEPT was selected for implementation in Flanders
based on the product's accumulated hemovigilance and clinical data,
which was thoroughly reviewed by the Belgian Red Cross Flanders as part
of the technology’s validation,” said Caspar Hogeboom, president of
Cerus Europe and EEMEA. “We are extremely pleased and proud to supply
INTERCEPT to all blood centers across Belgium, contributing toward the
country's goal of universal pathogen inactivation for platelets and
plasma.”
The Belgian Red Cross Flanders’ decision to proceed with the INTERCEPT
Blood System is a key step toward making pathogen inactivation the
standard of care in Europe. With approximately 65,000 platelet units
produced annually, Belgium joins countries such as Switzerland, Iceland
and Kuwait in making pathogen inactivated blood components generally
available for all patients.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood safety. Cerus currently markets and sells the INTERCEPT Blood
System for both platelets and plasma in Europe, the Commonwealth of
Independent States, the Middle East and selected countries in other
regions around the world. In the United States, Cerus is seeking
regulatory approval of the INTERCEPT Blood System for plasma and
platelets. The INTERCEPT red blood cell system is in clinical
development.
See http://www.cerus.com
for more information.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
Source: Cerus Corporation